Cibc World Market Inc. Purchases 1,225 Shares of Medpace Holdings, Inc. $MEDP

Cibc World Market Inc. grew its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 12.5% in the fourth quarter, Holdings Channel reports. The fund owned 11,013 shares of the company’s stock after acquiring an additional 1,225 shares during the quarter. Cibc World Market Inc.’s holdings in Medpace were worth $6,185,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Optiver Holding B.V. bought a new position in shares of Medpace in the 3rd quarter valued at $27,000. Geneos Wealth Management Inc. lifted its stake in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the last quarter. Steigerwald Gordon & Koch Inc. bought a new position in shares of Medpace in the 4th quarter valued at $30,000. Elyxium Wealth LLC bought a new position in shares of Medpace in the 4th quarter valued at $30,000. Finally, Quarry LP bought a new position in shares of Medpace in the 3rd quarter valued at $35,000. 77.98% of the stock is currently owned by institutional investors.

Medpace Price Performance

Shares of MEDP opened at $454.25 on Monday. The stock has a 50-day moving average of $456.73 and a 200-day moving average of $508.39. The company has a market cap of $12.97 billion, a PE ratio of 28.55, a P/E/G ratio of 2.30 and a beta of 1.18. Medpace Holdings, Inc. has a one year low of $294.07 and a one year high of $628.92.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, beating the consensus estimate of $3.74 by $0.54. The company had revenue of $706.60 million during the quarter, compared to the consensus estimate of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The firm’s revenue for the quarter was up 26.5% compared to the same quarter last year. During the same period last year, the business posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Analysts expect that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

Trending Headlines about Medpace

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Multiple law firms, including Rosen, Pomerantz, Schall, Faruqi & Faruqi, and others, reiterated that a class action has been filed against Medpace alleging violations of federal securities laws and investor harm. Article Title
• Negative Sentiment: The lawsuits center on purchases made between April 22, 2025 and February 9, 2026, with investors urged to act before the June 8 lead-plaintiff deadline, keeping legal risk and uncertainty in focus. Article Title
• Neutral Sentiment: One item noted a management change, with Medpace elevating Brad Hansman to an executive operations role, but this appears to be a routine corporate update with no immediate market-moving detail. Article Title

Wall Street Analyst Weigh In

Several research analysts recently issued reports on MEDP shares. Robert W. Baird lowered their target price on Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Truist Financial lowered their target price on Medpace from $555.00 to $539.00 and set a “hold” rating for the company in a research report on Wednesday, February 11th. Mizuho set a $582.00 target price on Medpace in a research report on Wednesday, February 11th. Jefferies Financial Group raised Medpace from a “hold” rating to a “buy” rating and set a $560.00 target price for the company in a research report on Friday, February 13th. Finally, TD Cowen raised Medpace from a “sell” rating to a “hold” rating and lowered their target price for the stock from $462.00 to $419.00 in a research report on Wednesday, February 18th. Four analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Medpace currently has an average rating of “Hold” and a consensus target price of $467.08.

Insider Activity

In other news, President Jesse J. Geiger sold 31,707 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the sale, the president directly owned 15,000 shares in the company, valued at $6,829,500. This trade represents a 67.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the sale, the general counsel owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. This represents a 44.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 20.50% of the company’s stock.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.